Mantle cell lymphoma diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(15 intermediate revisions by 2 users not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{Akram}}
{{CMG}}; {{AE}} {{Akram}}
== Overview ==
== Overview ==
Tissue [[biopsy]] (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==


=== Study of choice ===
=== Study of choice ===
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
* Tissue [[Biopsy punch|biopsy]] (nodal or extranodal) is the gold standard test for the [[diagnosis]] of mantle cell lymphoma.


OR
==== Histology ====
* The [[microscopic]] [[Histological|histological findings]] can be found [[Mantle cell lymphoma pathophysiology #Microscopic Pathology|'''here''']].


The following result of [gold standard test] is confirmatory of [disease name]:
==== Immunohistochemistry ====
* [Result 1]
* [[CD19]], [[CD20]], [[CD22]], [[CD43]], [[CD79a]], [[CD5]], and [[FMC7]] typically are positive, whereas [[CD23]], [[CD10]], [[CD200]], and [[BCL6]] are usually negative.<ref>{{Cite journal
* [Result 2]
| author = [[Francesco Bertoni]], [[Emanuele Zucca]] & [[Finbarr E. Cotter]]
 
| title = Molecular basis of mantle cell lymphoma
OR
| journal = [[British journal of haematology]]
 
| volume = 124
[Name of the investigation] must be performed when:
| issue = 2
* The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
| pages = 130–140
* A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.
| year = 2004
 
| month = January
OR
| pmid = 14687022
 
}}</ref><ref>{{Cite journal
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
| author = [[Chan Yoon Cheah]], [[John F. Seymour]] & [[Michael L. Wang]]
 
| title = Mantle Cell Lymphoma
OR
| journal = [[Journal of clinical oncology : official journal of the American Society of Clinical Oncology]]
 
| volume = 34
The diagnostic study of choice for [disease name] is [name of the investigation].
| issue = 11
 
| pages = 1256–1269
OR
| year = 2016
 
| month = April
There is no single diagnostic study of choice for the diagnosis of [disease name].
| doi = 10.1200/JCO.2015.63.5904
 
| pmid = 26755518
OR
}}</ref>
 
* [[Cyclin D1]] is positive in majority of the cases.
There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
* [[SOX11]] expression is useful if [[cyclin D1]] is negative.
 
*[[Ki-67]] should also be included in the initial work-up. [[Ki-67]] proliferation index of less than 30% is associated with a favorable [[prognosis]].<ref>{{Cite journal
OR
| author = [[Olaf Determann]], [[Eva Hoster]], [[German Ott]], [[Heinz Wolfram Bernd]], [[Christoph Loddenkemper]], [[Martin Leo Hansmann]], [[Thomas E. F. Barth]], [[Michael Unterhalt]], [[Wolfgang Hiddemann]], [[Martin Dreyling]] & [[Wolfram Klapper]]
 
| title = Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group
[Disease name] is primarily diagnosed based on the clinical presentation.
| journal = [[Blood]]
 
| volume = 111
OR
| issue = 4
 
| pages = 2385–2387
Investigations:
| year = 2008
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
| month = February
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
| doi = 10.1182/blood-2007-10-117010
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
| pmid = 18077791
 
}}</ref><ref>{{Cite journal
==== The comparison of various diagnostic studies for [disease name] ====
| author = [[R. Schaffel]], [[C. V. Hedvat]], [[J. Teruya-Feldstein]], [[D. Persky]], [[J. Maragulia]], [[D. Lin]], [[C. S. Portlock]], [[C. H. Moskowitz]] & [[A. D. Zelenetz]]
{|
| title = Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
| journal = [[Annals of oncology : official journal of the European Society for Medical Oncology]]
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Test
| volume = 21
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Sensitivity
| issue = 1
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specificity
| pages = 133–139
|-
| year = 2010
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 1
| month = January
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| doi = 10.1093/annonc/mdp495
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| pmid = 20019090
|-
}}</ref>
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 2
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|}
<small> [Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity</small>
 
===== Diagnostic results =====
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
* [Finding 1]
* [Finding 2]
 
===== Sequence of Diagnostic Studies =====
The [name of investigation] must be performed when:
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
* A positive [test] is detected in the patient, to confirm the diagnosis.
 
OR
 
The various investigations must be performed in the following order:
* [Initial investigation]
* [2nd investigation]
 
=== Name of Diagnostic Criteria ===
 
'''It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.'''
 
[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
 
OR
 
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
 
OR
 
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
 
OR
 
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
 
OR
 
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:
* Criteria 1
* Criteria 2
* Criteria 3
 
OR
 
'''IF there are clear, established diagnostic criteria'''
 
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
 
OR
 
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
 
OR
 
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
 
OR
 
'''IF there are no established diagnostic criteria'''
 
There are no established criteria for the diagnosis of [disease name].


==== Fluorescence in situ hybridization (FISH) ====
* [[FISH]] can be used to detect the [[Chromosomal translocation|translocation]] t(11;14), which is found in most of [[MCL]] patients.<ref>{{Cite journal
| author = [[Tsieh Sun]], [[Mary Lowery Nordberg]], [[James D. Cotelingam]], [[Diana M. Veillon]] & [[John Ryder]]
| title = Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma
| journal = [[American journal of hematology]]
| volume = 74
| issue = 1
| pages = 78–84
| year = 2003
| month = September
| doi = 10.1002/ajh.10356
| pmid = 12949897
}}</ref>
   
==== Karyotyping: ====
* [[Karyotyping]] can also be used to detect the [[translocation]] t(11;14), which is found in most of [[MCL]] patients.<ref>{{Cite journal
| author = [[Jordi Camps]], [[Itziar Salaverria]], [[Maria J. Garcia]], [[Esther Prat]], [[Silvia Bea]], [[Jessica C. Pole]], [[Lluis Hernandez]], [[Javier Del Rey]], [[Juan Cruz Cigudosa]], [[Marta Bernues]], [[Carlos Caldas]], [[Dolors Colomer]], [[Rosa Miro]] & [[Elias Campo]]
| title = Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines
| journal = [[Leukemia research]]
| volume = 30
| issue = 8
| pages = 923–934
| year = 2006
| month = August
| doi = 10.1016/j.leukres.2005.11.013
| pmid = 16448697
}}</ref>
   
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 05:04, 4 January 2019

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma diagnostic study of choice

on Mantle cell lymphoma diagnostic study of choice

Mantle cell lymphoma diagnostic study of choice in the news

Blogs on Mantle cell lymphoma diagnostic study of choice

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.

Diagnostic Study of Choice

Study of choice

  • Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.

Histology

Immunohistochemistry

Fluorescence in situ hybridization (FISH)

Karyotyping:

References

  1. ↑ Francesco Bertoni, Emanuele Zucca & Finbarr E. Cotter (2004). "Molecular basis of mantle cell lymphoma". British journal of haematology. 124 (2): 130–140. PMID 14687022. Unknown parameter |month= ignored (help)
  2. ↑ Chan Yoon Cheah, John F. Seymour & Michael L. Wang (2016). "Mantle Cell Lymphoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34 (11): 1256–1269. doi:10.1200/JCO.2015.63.5904. PMID 26755518. Unknown parameter |month= ignored (help)
  3. ↑ Olaf Determann, Eva Hoster, German Ott, Heinz Wolfram Bernd, Christoph Loddenkemper, Martin Leo Hansmann, Thomas E. F. Barth, Michael Unterhalt, Wolfgang Hiddemann, Martin Dreyling & Wolfram Klapper (2008). "Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group". Blood. 111 (4): 2385–2387. doi:10.1182/blood-2007-10-117010. PMID 18077791. Unknown parameter |month= ignored (help)
  4. ↑ R. Schaffel, C. V. Hedvat, J. Teruya-Feldstein, D. Persky, J. Maragulia, D. Lin, C. S. Portlock, C. H. Moskowitz & A. D. Zelenetz (2010). "Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma". Annals of oncology : official journal of the European Society for Medical Oncology. 21 (1): 133–139. doi:10.1093/annonc/mdp495. PMID 20019090. Unknown parameter |month= ignored (help)
  5. ↑ Tsieh Sun, Mary Lowery Nordberg, James D. Cotelingam, Diana M. Veillon & John Ryder (2003). "Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma". American journal of hematology. 74 (1): 78–84. doi:10.1002/ajh.10356. PMID 12949897. Unknown parameter |month= ignored (help)
  6. ↑ Jordi Camps, Itziar Salaverria, Maria J. Garcia, Esther Prat, Silvia Bea, Jessica C. Pole, Lluis Hernandez, Javier Del Rey, Juan Cruz Cigudosa, Marta Bernues, Carlos Caldas, Dolors Colomer, Rosa Miro & Elias Campo (2006). "Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines". Leukemia research. 30 (8): 923–934. doi:10.1016/j.leukres.2005.11.013. PMID 16448697. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mantle_cell_lymphoma_diagnostic_study_of_choice&oldid=1514391"